Which Factors Will Push The Hormone Refractory Prostate Cancer Market To Achieve $11.91 Billion By 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Present And Forecasted Size Of The Hormone Refractory Prostate Cancer Market?
The market size for hormone-refractory prostate cancer has seen a fast-paced growth in the past years. The market which was valued at $7.35 billion in 2024 is projected to escalate to $8.12 billion in 2025, representing a compound annual growth rate (CAGR) of 10.4%. The notable growth during the historic period can be credited to the rising prevalence of prostate cancer, an upswing in PSA (prostate-specific antigen) screening, heightened physician awareness and specialization, a surge in the usage of palliative care, and a growth in the number of clinical trials.
In the coming years, the market size for hormone-refractory prostate cancer is projected to experience significant expansion. It is estimated to reach a worth of $11.91 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.1%. The anticipated growth in this period is due to factors such as the increased application of genetic biomarkers, rise in the uptake of precision medicine, the broadening scope of PARP inhibitors, enhanced worldwide access to HRPC treatments, and the increasing clinical use of combined regimens. The major trends anticipated for the forecast period include the growing preference for combination therapies, advancements in radiopharmaceuticals, the application of next-generation sequencing (NGS), the integration of digital tools and remote monitoring, and the development of next-generation androgen receptor inhibitors and PARP inhibitors specifically for HRPC.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25786&type=smp
What Underlying Factors Are Supporting The Hormone Refractory Prostate Cancer Market Growth?
The hormone-refractory prostate cancer market is anticipated to experience accelerated growth, given the escalating investment in cancer research. Such investments provide financial and resource backing aimed at furthering the development of novel cancer detection strategies, treatments, and preventive measures. A significant surge in global cancer cases is the primary reason for this increase in research funding, necessitating more tailored and efficacious treatments. Cancer research investments are spearheading innovation in managing hormone-refractory prostate cancer by facilitating cutting-edge therapies like radioligand treatments and hormone inhibitors, as well as supporting clinical trials and biomarker research to improve treatment accuracy and results. For instance, the Cancer Research Institute (CRI), a U.S.-based nonprofit organization committed to promoting immunotherapy research, in August 2024, invested approximately $22.8 million during the 2023-2024 fiscal year, awarding 64 new grants to researchers from 42 institutions in seven nations. Consequently, the escalating investment in cancer research stands as a significant factor propelling the growth of the hormone-refractory prostate cancer market.
How Does The Hormone Refractory Prostate Cancer Market Differ By Segment?
The hormone refractory prostate cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Estramustin
2) By Hormonal Therapy: Anti-Androgens, CYP17 Inhibitors, LHRH Agonists, LHRH Antagonists
3) By Immunotherapy: Cancer Vaccines, Immune Checkpoint Inhibitors, Adoptive Cell Therapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radionuclide Therapy
5) By Surgery: Radical Prostatectomy, Orchiectomy, Transurethral Resection Of The Prostate (TURP)
What New Opportunities Are Emerging From Trends In The Hormone Refractory Prostate Cancer Market?
Major firms active in the hormone-refractory prostate cancer market like Novartis AG, are prioritising the development of innovative therapies such as intravenous radioligand therapy. This advanced treatment targets and destroys cancer cells from within while leaving healthy cells unharmed, thereby enhancing patient survival rates. As an example, in March 2025, the Switzerland-based pharmaceutical giant launched Pluvicto (lutetium Lu 177 vipivotide tetraxetan), gaining Food and Drug Administration (FDA) approval. This drug was developed for early usage in patients suffering from prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC), who have previously been treated with an androgen receptor pathway inhibitor (ARPI), and are suitable candidates for postponing chemotherapy. The extended application of Pluvicto, justified by the results of the Phase III PSMAfore trial, is expected to triple the number of eligible patients. The trial results showed that Pluvicto decreased the risk of radiographic progression or death by 59%, while more than doubling median radiographic progression-free survival compared to a change in ARPI. This makes Pluvicto the first approved targeted radioligand therapy to be used before chemotherapy in this context, providing a novel therapeutic option that can defer disease progression while having a positive safety profile.
Who Are The Global Leaders Steering The Hormone Refractory Prostate Cancer Market Forward?
Major companies operating in the hormone refractory prostate cancer market are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Ipsen Pharma, Exelixis Inc., Orion Corporation, Lantheus Holdings Inc., Clovis Oncology Inc., Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC
Access The Complete Report Here:
Which Region Is Likely To Register The Fastest Growth In The Hormone Refractory Prostate Cancer Market?
North America was the largest region in the hormone-refractory prostate cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormone refractory prostate cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25786&type=smp
Browse Through More Reports Similar to the Global Hormone Refractory Prostate Cancer Market 2025, By The Business Research Company
Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Global Market Report 2025
Drugs For Benign Prostatic Hypertrophy Global Market Report 2025
Urinary Tract Cancer Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/urinary-tract-cancer-global-market-report
About The Business Research Company:
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
